INBRX-106 in Combination With Pembrolizumab in First-line PD-L1 CPS≥20 HNSCC
← catalyst calendarNCT06295731 · readout ≤ 1,016 d
Sponsored by Inhibrx Biosciences, Inc (industry) · INBX — their whole pipeline →.
Phase
Phase 2/3
Status
Active, not recruiting
Study type
Interventional
Design
Randomized · Double · Treatment
Enrollment
410estimated
Sites
87
Countries
Australia, Belgium, Bulgaria +10
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-05-14 | actual | When the study began enrolling |
| Primary completion | May 2029 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | May 2029 | estimated | The whole study's end, after follow-up |
| First posted | 2024-03-06 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-05-08 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Head and Neck Squamous Cell Carcinoma (HNSCC)
Interventions
- Drug: INBRX-106 — also filed as Hexavalent OX40 agonist antibody
- Drug: Pembrolizumab — also filed as Keytruda
Primary outcomes
what the primary-completion date above is the date OFPhase 2: Objective Response Rate (ORR)
measured up to 6 months
Phase 3: Progression-Free Survival (PFS)
measured From randomization to first occurrence of progressive disease (PD) or death (up to 4 years)
Phase 3: Overall Survival (OS)
measured From randomization until death from any cause (up to 4 years)
Permalink · INBX's whole pipeline · Catalyst calendar · Every registered study · What changed